A new treatment for low-grade kidney/ureter cancer (ST-02)
Part of Cancer, Kidney & urinary clinical trials.
This trial tests a new treatment called ST-02 that is given directly into the kidney or ureter to destroy low-grade cancer cells without surgery. It may be an option for people whose cancer has not spread and who are looking for a less invasive treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old
- You have low-grade, non-invasive cancer in the kidney or upper ureter (confirmed by biopsy or urine test within 8 weeks)
- At least one tumor is between 0.5 and 1.5 cm (about the size of a pea to a small grape)
- Your kidney function is good enough (eGFR of 10 or higher) and you do not have an active urinary tract infection
- You are not pregnant, not breastfeeding, and willing to use effective birth control during treatment and for 6 months after
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving radiation therapy before surgery can help people with high-risk upper tract urothelial cancer (UTUC). The goal is to improve treatment outcomes for patients who are planning to have their cancer removed.
This trial tests a combination of a targeted drug (disitamab vedotin), an immunotherapy (toripalimab), and radiation before surgery for people with high-risk upper tract urothelial cancer (UTUC). The goal is to see if this approach improves outcomes before and after surgery.
This trial is testing whether adding immunotherapy and radiation after surgery can improve outcomes for people with advanced upper tract urothelial cancer (UTUC) who cannot have chemotherapy. It compares the combination to surgery alone.
This Phase 2 trial studies whether a combination treatment can control high-grade upper tract urothelial cancer without removing the kidney and ureter (radical nephroureterectomy). It may help people who must avoid surgery or choose not to have it because of medical risk.
This trial tests a combination of treatments to save the kidney in people with high-risk upper tract urothelial carcinoma. The goal is to remove the cancer while keeping the kidney working, which may be an option if your cancer is at an early stage and your kidney function is good enough.
This Phase 2 trial studies a HER2-targeted medicine (RC48-ADC) plus another drug (JS001) to help prevent cancer from coming back after surgery for upper urinary tract urothelial cancer. It may be an option if your tumor has higher HER2 levels and you have no spread to distant organs.
Hear when a new Urothelial Carcinoma of the Renal Pelvis and Ureter trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.